Table 1. Clinical and anatomical features of 20 PCNSL patients†.
| Case | Sex | Age (years) | Tumor location | Ki 67* |
|---|---|---|---|---|
| 1 | M | 40 | Parieto-frontal lobe | 80 |
| 2 | M | 74 | Occipital lobe | 75 |
| 3 | M | 82 | Occipital lobe | 40 |
| 4 | M | 69 | Parietal lobe | 95 |
| 5 | M | 72 | Parieto-temporal lobe | 60 |
| 6 | M | 58 | Temporal lobe | 70 |
| 7 | M | 72 | Basal ganglia | 90 |
| 8 | F | 65 | Cerebellar | 80 |
| 9 | M | 72 | Frontal lobe and corpus callosum | 75 |
| 10 | F | 75 | Temporal lobe | 70 |
| 11 | M | 66 | Frontal lobe | 85 |
| 12 | M | 64 | Parieto-frontal lobe | 80 |
| 13 | M | 73 | Parieto-frontal lobe | 80 |
| 14 | F | 38 | Multiple intra-cerebral | 65 |
| 15 | M | 58 | Occipital lobe | 80 |
| 16 | M | 72 | Parietal lobe | 45 |
| 17 | F | 64 | Parieto-occipital lobe | 80 |
| 18 | M | 37 | Basal ganglia | 80 |
| 19 | F | 67 | Basal ganglia | 80 |
| 20 | M | 44 | Cerebellar | 40 |
*Ki -67 tumor proliferative index.
†All the patients have high degree of tumor and have been treated with a classic schema of chemotherapy, including methotrexate + Cytarabine (araC).